Arvind is Chief Operating Officer at Redenlab and brings deep expertise across strategy, operations and finance. He was previously Vice President at Atai Life Sciences, a neuropsychiatry biopharmaceutical, where he was responsible for building Atai’s digital function and was part of the senior leadership team that listed Atai on the Nasdaq. Prior to Atai, he was Chief Operating Officer of OxfordVR, an Oxford University spin-out focused on treating Schizophrenia in the UK’s NHS. Arvind began his career in M&A and private equity, and studied Molecular and Cellular Biochemistry at Oxford University.